BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced new interim data published from the large ...
(Singapore--4:45 p.m. SPT/3:45 a.m. EST January 30, 2021--Using a host immune classifier (HIC) test for patients with non-small cell lung cancer (NSCLC) may provide better predictors of treatment ...
Prevalence of STK11, KEAP1, and KRAS mutations/co-mutations and associated clinical outcomes for patients newly diagnosed with metastatic non-small cell lung cancer. This is an ASCO Meeting Abstract ...
Patients treated with immune checkpoint inhibitors had significantly different survival rates based on the test, regardless of PD ligand 1 classification. A blood-based proteomic test can help ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback